Background-Although the reduction in mortality with bivalirudin compared with unfractionated heparin plus glycoprotein IIb/IIIa inhibitors in the Harmonizing Outcome with Revascularization and Stent in Acute Myocardial Infarction (HORIZONS-AMI) trial has been attributed to lower rates of major bleeding, alternative mechanisms have not been investigated in depth. We sought to investigate whether there might be an interaction between white blood cell (WBC) count and bivalirudin for the risk of mortality, and whether this interaction is independent of major bleeding. Methods and Results-Among the 3602 patients enrolled in the HORIZONS-AMI trial, WBC count was available in 3433 (95.3%) patients. Patients were stratified according to WBC tertiles. At 1-year follow-up, bivalirudin was associated with significantly lower rates of mortality and cardiac mortality compared with unfractionated heparin plus glycoprotein IIb/IIIa inhibitors in patients in the upper WBC tertile (all-cause death: 4.1% versus 9.3%, respectively; P=0.0004; cardiac death: 2.0% versus 6.9%; respectively; P<0.0001) but not in patients in the mid-WBC or lower WBC tertiles. The reduction of mortality with bivalirudin across WBC tertiles was independent of major bleeding, and a significant interaction was apparent for 1-year all-cause mortality and cardiac mortality between WBC and bivalirudin therapy. Similar findings were apparent at 3 years. Conclusions-In patients with ST-segment-elevation myocardial infarction, a significant interaction between bivalirudin therapy and admission WBC count was apparent for 1-year mortality. The reduction in mortality was independent of major bleeding, suggesting that other mechanisms may be implicated in the survival benefit observed with bivalirudin. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00433966.
I n the large-scale, prospective, randomized Harmonizing Outcome with Revascularization and Stent in Acute Myocardial Infarction (HORIZONS-AMI) trial, anticoagulation with bivalirudin compared with unfractionated heparin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) significantly reduced 30-day rates of major bleeding and net adverse clinical events. 1 Moreover, patients treated with bivalirudin had significantly reduced rates of mortality and cardiac mortality compared with patients treated with UFH plus GPI at 3-year follow-up. 2 Although lower rates of death observed with bivalirudin were attributed to the marked reduction in major bleeding, alternative mechanisms have not been investigated in depth.
We have recently reported that white blood cell (WBC) count is an independent predictor of mortality, cardiac mortality, and major bleeding in patients with ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention. 3 In the present study, we hypothesized that there might be an interaction between WBC count and the efficacy of antithrombotic treatments, and we investigated whether this interaction is independent of major bleeding.
Methods
The study design of the HORIZONS-AMI trial has previously been reported in detail. 4 Briefly, HORIZONS-AMI was a prospective, randomized trial including consecutive patients aged ≥18 years who presented within 12 hours after the onset of symptoms with STsegment-elevation of ≥1 mm in ≥2 contiguous leads, with new left bundle branch block, or with true posterior infarction. Patients were randomized before angiography in a 1:1 ratio to anticoagulation with the direct thrombin inhibitor bivalirudin or to UFH plus GPI. After angiography, stent-eligible patients were randomized in a 3:1 ratio to paclitaxel-eluting stents versus bare metal stents. All adverse cardiac and bleeding events were adjudicated by an independent clinical events committee blinded to treatment assignment. The study was approved by the institutional review board or ethics committee at each participating center, and all patients provided written informed consent. Blood samples were obtained at the time of admission from each participating center, and observations were recorded in the electronic case report form. Total WBC count was measured in an EDTAanticoagulated whole-blood specimen. The authors had full access to the data and take full responsibility for the integrity of data. All authors have read and agreed to the article as written.
Study Objectives and Definitions
The primary objective of this study was to evaluate whether there might be an interaction between WBC measured at hospital admission and bivalirudin therapy for the risk of cardiac mortality. Secondary analyses were performed in patients with all-cause mortality, cardiac mortality, myocardial infarction, non-coronary artery bypass graft (CABG)-related major bleeding, and stent thrombosis. The primary end point definitions in the HORIZON trial have been reported in detail previously. 4 In addition, cardiac mortality was adjudicated as death because of any of the following: acute myocardial infarction, cardiac perforation or pericardial tamponade, arrhythmia or conduction abnormality, stroke, and procedural complication. Any death in which a cardiac cause could not be excluded was also adjudicated as cardiac mortality. Renal dysfunction was defined as a creatinine clearance of <60 mL/min calculated by the Cockcroft-Gault equation. Stent thrombosis was defined according to the Academic Research Consortium definition. 5
Statistical Analysis
Continuous data were presented as mean±SD or median (Q1-Q3) and were compared using the Student t test or the Mann-Whitney ranksum test, as appropriate. Categorical variables were compared by χ 2 or Fisher exact test. All outcomes were analyzed after stratifying patients by WBC tertiles and antithrombotic treatments. Time-to-event outcomes were analyzed by Kaplan-Meier analysis, and differences were compared using the log-rank test. Landmark analyses of mortality and cardiac mortality were performed in the period between index hospitalization and 30 days, 31 days and 1 year, and 1 to 3 years.
Stepwise multivariable Cox regression analyses were performed to assess independent predictors of mortality and cardiac mortality at 1 and 3 years. These analyses were performed both in the whole cohort of patients and in those who did not develop non-CABG-related major bleeding. Formal interaction testing was performed to determine whether differential effects of bivalirudin treatment were apparent across tertiles of WBC for 1-year all-cause mortality and cardiac mortality. Entry and exit criteria for candidate variables to be retained in the stepwise models were set at P=0.1, with bivalirudin, WBC tertiles, and the interaction between these 2 variables being first forced into the models. To avoid model overfitting, only variables known to affect prognosis in ST-segment-elevation myocardial infarction were considered, and they are specified for each analysis in the corresponding table. Because left ventricular ejection fraction at hospital admission was not available in 472 patients, multivariable analyses of 1-year mortality and cardiac mortality were performed both in the whole cohort of patients and in the subset of patients who had left ventricular ejection fraction determined. There were no adjustments for multiple statistical testing. Statistical analyses were performed using SAS version 9.1. P<0.05 was considered statistically significant.
Results

Patients
Among the 3602 patients enrolled in the trial, WBC count was available in 3433 (95.3%) patients. Clinical, angiographic, and procedural characteristics of patients stratified by tertiles of WBC count and antithrombotic treatments are shown in Table 1 and Table I in the online-only Data Supplement. There was no significant difference in the baseline clinical characteristics between patients randomized to bivalirudin versus UFH plus GPI across tertiles of WBC, except for higher ischemic times and a lower percentage of preprocedural Thrombolysis In Myocardial Infarction flow 0/I in patients in the upper tertile of WBC treated with UFH plus GPI compared with bivalirudin. Moreover, a significantly higher proportion of male patients were treated with bivalirudin than with UFH plus GPI in the intermediate WBC tertile.
One-Year and 3-Year Clinical Outcomes
Clinical outcomes of patients stratified by tertiles of WBC count and bivalirudin therapy up to 3-year follow-up are shown in Table 2 . At 1-year follow-up, bivalirudin was associated with significantly lower all-cause mortality and cardiac mortality compared with UFH plus GPI in patients in the upper tertile of WBC (all-cause death: 4.1% versus 9.3%, respectively; P=0.0004; cardiac death: 2.0% versus 6.9%; P<0.0001) but not patients in intermediate (all-cause death: 3.3% versus 2.1%; P=0.21; cardiac death: 2.1% versus 1.9%; P=0.84) or lower WBC tertiles (all-cause death: 2.8% versus 3.1%; P=0.80; cardiac death: 2.0% versus 2.2%; P=0.87). Of note, when compared with UFH plus GPI, bivalirudin reduced major non-CABG bleeding to a greater extent in patients in the highest WBC tertile than in patients in the lower 2 tertiles ( Table 2) .
Similar results were apparent at 3-year follow-up, with bivalirudin significantly reducing mortality ( Figure I • The reduction of bleeding with bivalirudin is predominantly responsible for the concomitant improvement in survival.
WHAT THE STuDY ADDS
• This is the first study showing that leukocyte count is a modulating factor for the mortality benefit of bivalirudin in ST-segment-elevation acute myocardial infarction.
• There is a significant interaction between leukocyte count and bivalirudin therapy for the reduced risk of 1-year cardiac mortality.
• This interaction is independent of the occurrence of major bleeding.
tertile but not in patients in the mid-WBC or lower WBC tertiles. When the analysis was restricted to patients who did not develop non-CABG-related major bleeding during follow-up (n=3141), again bivalirudin significantly reduced 3-year allcause mortality ( Figure II Figure 3 ) showed that the difference between the 2 antithrombotic treatments in the upper tertile of WBC was the greatest during the first 30 days after percutaneous coronary intervention and was still significant between 31 days and 1 year and vanished between 1 and 3 years, whereas the curves were almost superimposable in each interval of time in the lower 2 tertiles. As shown in Figure 4 , a significant interaction was apparent between WBC tertiles and bivalirudin for the risk of 1-year cardiac mortality.
Table 1. Baseline Clinical Characteristics of Patients Stratified by White Blood Cell Count and Antithrombotic Therapy
Multivariable Analysis
Independent predictors of 1-year mortality and cardiac mortality are reported in Table 3 . After correcting for main confounders, including major bleeding, the interaction between WBC tertiles and bivalirudin monotherapy for 1-year all-cause mortality and cardiac mortality remained significant. Of note, this interaction remained significant also in the subgroup of patients who had left ventricular ejection fraction determined (Table II in the online-only Data Supplement) and in the subgroup of patients who did not develop non-CABG-related major bleeding (Table 3 ). Independent predictors of 3-year mortality and cardiac mortality in the whole cohort of patients are shown in Table III in the onlineonly Data Supplement. Bivalirudin was an independent predictor of 3-year cardiac mortality, whereas WBC count was an independent predictor of both cardiac and all-cause mortality.
Discussion
Although in the HORIZONS-AMI trial bivalirudin was associated with lower rates of cardiac mortality compared with UFH plus GPI, the mechanisms behind this association have not been investigated in depth. The main findings of the present analysis are (1) the effect of bivalirudin on mortality varied in relation to WBC count, with bivalirudin significantly reducing 3-year rates of all-cause mortality and cardiac mortality in patients in the upper tertile of WBC count but not in patients in the mid or lower tertiles of WBC; (2) the difference in mortality between bivalirudin and UFH plus GPI in patients in the upper WBC tertile occurred during the first year of follow-up, and a significant interaction between WBC tertiles and bivalirudin was apparent for both 1-year all-cause mortality and cardiac mortality; and (3) the significant interaction between bivalirudin therapy and WBC tertiles for 1-year mortality was independent of major bleeding.
In the HORIZONS-AMI trial, treatment with bivalirudin monotherapy resulted in significantly reduced rates of bleeding and mortality compared with treatment with UFH plus GPI. 2 Because bleeding has been associated with increased rates of both short-and long-term mortality, 6,7 a mechanistic association between these 2 variables has been suggested to explain the results of the HORIZONS-AMI trial. The most important and unexpected finding of this study is that the reduction in mortality with bivalirudin compared with UFH plus GPI was independent of major bleeding, and the reduction was modulated by WBC count. These results therefore challenge the current paradigm that the reduction in bleeding with bivalirudin is predominantly responsible for improvement in survival and suggest that alternative mechanisms may also play an important role. In this study, we found that WBC count modulates the efficacy of antithrombotic treatments, with bivalirudin significantly reducing the risk of mortality in patients in the upper tertile of WBC count but not in patients in the intermediate or lower tertiles of WBC. The difference in mortality between bivalirudin and UFH plus GPI was apparent at 30 days and continued to accrue between 31 days and 1 year, whereas no significant difference in mortality between the 2 antithrombotic treatments was apparent beyond 1 year. Accordingly, a significant interaction was apparent between WBC tertiles and bivalirudin for 1-year all-cause mortality and cardiac mortality. Importantly, this interaction was independent of major bleeding.
Although this study does not prove causality, there are several biological mechanisms that may explain the interaction between antithrombotic treatments and high WBC for 1-year mortality. Some studies have in fact reported that UFH plus eptifibatide, but not bivalirudin, may cause neutrophil activation and mieloperoxidase release in patients undergoing percutaneous coronary intervention. 8 Further studies have shown that UFH promotes proinflammatory interactions between platelets and WBC, increasing platelet reactivity and favoring formation of platelet-leukocyte aggregates 9 and monocyte tissue factor expression. 10 In contrast, treatment with bivalirudin compared with UFH has been associated with attenuation of inflammation after elective percutaneous coronary intervention 11 or in animal models of cardiopulmonary bypass. 12 Moreover, in a substudy of the Intracoronary Stenting and Antithrombotic Regimen Rapid Early Action for Coronary Treatment (ISAR-REACT) 3 trial, platelet surface expression of PAC 1 and P-selectin and monocyte surface expression of CD11b were significantly lower with bivalirudin than with UFH. 13 Therefore, the benefit of bivalirudin over UFH may become particularly evident in clinical contexts of enhanced systemic inflammation, such as ST-segment-elevation myocardial infarction, where the negative effect of heightened inflammation may be exacerbated by UFH and attenuated by bivalirudin. Consistent with this hypothesis, in our study 1-year cardiac mortality significantly increased from 3.5% in the lower WBC tertile to 7.9% in the upper WBC tertile in patients treated with UFH plus GPI, whereas it was nearly unchanged (2.4% versus 3.0%, respectively) in patients treated with bivalirudin.
As previously reported, bivalirudin was associated with a significant decrease in major bleeding. 1 In the present study, we also report that the magnitude of this effect depended on WBC count. In particular, a gradient of risk was apparent between bivalirudin versus UFH plus GPI across WBC tertiles, with no significant difference in the risk of 30-day major bleeding between the 2 antithrombotic treatments in the lower WBC tertile, a 33% relative risk reduction with bivalirudin in the intermediate WBC tertile, and a 52% relative risk reduction in the upper WBC tertile. Noteworthy, when considering the more restrictive definition of Thrombolysis In Myocardial Infarction major bleeding, the reduced risk of bleeding with bivalirudin was apparent only in patients in the upper tertile of WBC. These data suggest that the higher the WBC count, the greater the effect of bivalirudin in reducing the risk of bleeding. However, because this was not the primary objective of this study, we did not assess whether this association was independent from other confounders or whether there might be an interaction between bivalirudin and WBC count for the risk of bleeding. These findings should therefore be considered hypothesis-generating, warranting further investigation.
This study has several limitations that should be acknowledged. As an observational investigation, it can only identify correlations and not prove causality. Despite adjustment for potential confounders, unmeasured variables may not have been controlled for. All these findings, therefore, should be considered hypothesis-generating. WBC count was determined at only 1 time point and, therefore, may have been subject to regression dilution bias. Information on the WBC differential count was not available, and therefore, we could not investigate whether the interaction between WBC and antithrombotic treatments was specific to only a subset of the leukocyte population.
In conclusion, among patients with ST-segment-elevation myocardial infarction enrolled in the HORIZONS-AMI trial, admission WBC count significantly interacts with antithrombotic treatments, with bivalirudin significantly reducing the risk of mortality and cardiac mortality in patients in the upper WBC tertile but not in patients in the intermediate or lower tertile of WBC. This preferential effect is largely independent of the occurrence of non-CABG major bleeding.
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